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Abstract 
To date the importance of luminal species other than bile salts and phosphatidylcholine on drug 
equilibrium solubility in the fasted upper small intestine has been evaluated to a very limited extent. In this 
communication the importance of fatty acids, cholesterol, and proteins on solubility of four model 
lipophilic compounds was evaluated by including these components into previously proposed simulated 
intestinal fluids. Data were compared with ex vivo solubility data in aspirates reflecting the mean and the 
median luminal composition in the upper small intestine. It is concluded that estimation of solubility in 
aspirates reflecting the median luminal composition is better estimated when the presence of cholesterol 
and fatty acids is also simulated. In contrast, estimation of solubility in aspirates reflecting the mean 
luminal composition requires consideration of additional factors (e.g. buffer species identity, non-micellar 
colloidal structures, and lyso-phosphatidylcholine content). 
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Introduction 
Drug equilibrium solubility in the contents of upper intestinal lumen is an important factor for the oral 
absorption process as it determines the maximum dose which can be absorbed and it affects luminal drug 
dissolution rates. In case the active pharmaceutical ingredient (API) is lipophilic, luminal colloidal species 
(e.g. mixed bile salt micelles) greatly enhance luminal solubility and relevant information is crucial for 
predictions of drug plasma levels after oral administration of conventional dosage forms, e.g. when 
physiologically based pharmacokinetic modelling approaches are applied [1]. 
Luminal equilibrium solubility can be estimated by data in simulated intestinal fluids [e.g. 2,3]. 
Composition of relevant fluids is a balance between the actual luminal environment, the importance of 
specific luminal components, and, sometimes, the costs associated with their reproducible preparation 
methods and storage conditions. To date, the importance of certain luminal components which may have 
an impact on luminal solubility of lipophilic APIs in the fasted state, such as fatty acids, cholesterol and 
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proteins, has not been considered. Such components have been recently shown to have a role in luminal 
precipitation of lipophilic weak bases [4]. 
The objective of this communication was to evaluate the usefulness of various fasted state simulating 
intestinal fluids in predicting solubility in the upper small intestine of four model lipophilic compounds 
(Table 1) with emphasis to components which are present in the upper small intestine but their importance 
has not been evaluated to date. Simulated intestinal fluids were prepared by using crude bile salt material 
which had been previously analyzed in our laboratory for its exact bile salt content. Data in simulated 
intestinal fluids were compared with data in human aspirates. Since it is not clear whether the average 
luminal composition should be considered on the basis of mean or of median luminal composition [5], in 
the present study two pooled aspirates samples that reflected the mean and the median luminal 
composition were used. 
 









Molecular Weight 368.5 531.4 357.8 337.5 
clogP 5.19 3.65 3.66 4.5 
pKa 7.78  2.94 and 6.51 (both alkaline)  4.5 - 
Aqueous Solubility 
(µg/mL) 
0.29  0.0866 0.937 1.1 
 
Experimental 
Cinnarizine was from Janssen Cilag AEBE (lot # 1001105726, Athens, Greece), ketoconazole was from 
Recordati Espana S.L. (lot # 03000051, Beniel, Spain), indomethacin was from F.I.S. Fabrica Italiana Sintetici 
S.p.A. (lot # 0907105123, Vicenza, Italy) and danazol was from Sanofi-Aventis (batch # F510357, Fawdon, 
France). Egg lecithin (Lipoid E PC, > 98 % phosphatidylcholine) was from Lipoid GmbH (Ludwigshafen, 
Germany). Ox bile salt extract was from Fluka Chemie GmbH, Germany (product No 86340, lot # 386645/1 
12601). According to our HPLC-CAD analysis [12] the total bile salts content of the crude material used in 
the presenet study is 71.5 % w/w, and the following bile acids are present: taurocholic 22.2 % w/w, 
glycocholic 24.7 % w/w, taurochenodeoxycholic 1.7 % w/w, ursodeoxycholic 7.1 % w/w, 
glycochenodeoxycholic 1.3 % w/w, cholic 7.5 % w/w, glycodeoxycholic 7.1 % w/w. [3]. Albumin from 
bovine serum, BioChemika Fraction V was from Fluka (cat # 05488, lot # S31293-466). Methanol and 
acetonitrile of HPLC grade were from E. Merck (Darmstadt, Germany). Water purified with Labconco water 
pro ps system (Kansas City, Missouri, USA) was used in all procedures. All other chemicals were of 
analytical grade. 
Individual human aspirates were collected from the ligament of Treitz after receiving approval by the 
Ethical Committee of the Red Cross Hospital of Athens (A.P. 497 / 06.12.2011). Samples were selected and 
pooled so that the pooled sample had composition similar to the mean composition of intraluminal 
contents [5], HIFmean. In addition, samples were selected and pooled so that the pooled sample had 
composition similar to the median composition of intraluminal contents [5], HIFmedian (Table 2). Due to 
multiple freeze – thawing processes, pH of both HIFmean and HIFmedian used in the solubility 
measurements was increased from 6.5 (aspiration time) to 7.5. 
FaSSIF [13] and FaSSIF-V2 [2] reflect the mean environment in the fasted upper small intestine. 
Recently, FaSSIF-V2Plus was proposed for predicting the precipitation of weak bases in the upper small 
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intestine [4]. In the present investigation, all these media were prepared by using crude bile material (ox 
bile salt extract) and used for measuring the solubility of the four model APIs (Table 1). The importance of 
phosphatidylocholine concentration (0.75, 1, 1.5 mM) and of bovine serum albumin concentration (BSA 
0.5-4 mg/ml) on the predictability of luminal solubility of ketoconazole, indomethacin and danazol were 
also evaluated. Compositions of simulated intestinal fluids used in the presented study is shown in Table 2. 
Finally, solubilities of ketoconazole, indomethacin and danazol were also measured in buffer solutions of 
phosphates and maleates having pH values of 6.5. 
Solubilities were measured in triplicate using the shake-flask method. For solubility measurements in 
human intestinal fluids, 1 ml of HΙF and pure drug powder in excess (1 mg for cinnarizine, 15 mg for 
ketoconazole, 5 mg for indomethacin and 1 mg for danazol) were transferred into 2-ml polypropylene vials. 
Vials were then sealed with polypropylene caps, and put in an oscillating water bath (37 °C). Equilibration 
times were experimentally determined or had already been determined previously using similar media 
volumes (1-5 ml) and the same in vitro setup [3,10,14,15]. Equilibration times were 2 h (cinnarizine), 8 h 
(ketoconazole), 2 h (indomethacin) and 4 h (danazol). After reaching equilibrium, and since HΙFs could not 
be filtered through 0.45 μm filters, samples were centrifuged for 10 min at 11500 g at 37 °C. After 
measuring the pH, the supernatant was appropriately diluted with acetonitrile, centrifuged again (10 min, 
11500 g, 10 °C) and assayed for drug concentration using validated HPLC-UV methods. For solubility 
measurements in simulated intestinal fluids, 5 ml of the medium and pure drug powder in excess (5 mg for 
cinnarizine, 175 mg for ketoconazole, 25 mg for indomethacin and 5 mg for danazol) were transferred into 
10-ml polypropylene vials. Vials were then sealed with high density polypropylene caps and put in an 
oscillating water bath (37 °C) for periods identical to those used in the experiments in human intestinal 
fluids (please see above). After reaching equilibrium, samples were filtered through 0.45 μm regenerated 
cellulose filters (adsorption to filters was measured to be negligible), the filtrates were diluted 
appropriately diluted with acetonitrile and assayed for their drug content using validated HPLC-UV 
methods. 
APIs were evaluated for their stability in solubility media prior to solubility measurements. 
Ketoconazole, indomethacin and danazol were found to be stable in all media tested in this study. For 
cinnarizine, a portion of the pooled sample reflecting HIFmean was transferred in a test tube, cinnarizine in 
excess was added, the tube was sealed and it was incubated at 37 °C in a shaking water bath. Four hours 
after the initiation of shaking the contents of the tube were centrifuged (11500 g, 37 oC, 10 min). pH of the 
supernatant was measured to be 7.8. A sample from the supernatant was analyzed immediately for its 
cinnarizine content (content at time t=0) and the remaining was transferred in another tube, sealed and 
incubated for 20 hours at 37 °C in the same shaking water bath. Samples were obtained 0.5, 1, 1.5, 2, 3.2 
and 20 hours after the initiation of the incubation of the filtrate. 
All model compounds were assayed with HPLC-UV methods (Table 3). For each drug/medium 
combination, quantification was based on linear standard curves constructed using the same medium and 
identical sample handling procedure. 
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Table 3. The chromatographic conditions used for the analysis of drugs in the present study 
Chromatographic 
Conditions 























Flow Rate (ml/min) 1 1 1 1.3 
Detection wavelength 
(nm) 
254 240 266 286 
Injection volume (μl) 20 20 20 20 
 
Results and Discussion 
Cinnarizine was unstable in the pooled HIF sample reflecting HIFmean. Figure 1 shows the cinnarizine 
degradation profile in the pooled HIF sample at 37 °C together with the characteristics of the best fitted 
line drawn by using the data up to 3.20h. Estimated degradation half-life is 1.44h. Interestingly, solubility of 
cinnarizine has been previously reported to be 32.011.8 μg/ml and 47.317.4 μg/ml in HIFs and FaSSIF, 
respectively [16]. After reaching equilibrium in plain phosphate and plain maleate buffers filtrates were 
incubated at 37 °C for 48h at which time their cinnarizine content was measured to be zero. Therefore, 
stability of cinnarizine in simulated intestinal media is also an issue. During the equilibration period, 
concentration peaked at 4h after initiation of oscillation, and this was considered as “apparent cinnarizine 
solubility”. Apparent solubility in FaSSIFcr-V2Plus was significantly higher than in FaSSIFcr-V2 (Figure 2), i.e. 
inclusion of sodium oleate and cholesterol in increased the solubility of cinnarizine. This is in line with the 
high lipophilicity of the compound (Table 1) and previously collected data on the effects of lipids on the 
solubilization capacity of mixed bile salt micelles for highly lipophilic compounds [17]. 
 
 




































































Figure 2. Mean+SD (n=3) apparent cinnarizine solubility in simulated intestinal fluids (37 
o
C). Please see in Table 2 and 
in the text for compositions of simulated intestinal fluids. 
 
FaSSIFcr-V2 was less useful than FaSSIFcr in the prediction of ketoconazole, indomethacin, and danazol 
solubility in the pooled sample reflecting HIFmean (Figure 3). Unlike with cinnarizine, inclusion of 
biorelevant concentrations of cholesterol and sodium oleate in FaSSIFcr-V2 (i.e. FaSSIFcr-V2Plus) did not 
have significant impact on solubility of ketoconazole and danazol. Also, the impact of BSA on ketoconazole, 
indomethacin, and danazol solubility in FaSSIFcr and FaSSIFcr-V2 was minimal (data not shown). This is in 
line with previous data indicating that luminal proteins may not be important to luminal drug solubility or 
their global simulation should be done cautiously [3]. In contrast, by increasing phosphatidylocholine 
concentration in FaSSIF-V2 to 1mM, ketoconazole and danazol solubility in the pooled sample reflecting 
HIFmean were successfully estimated (FaSSIFcr-V21,PC, Figure 3). 
FaSSIFcr-V2plusmedian led to successful estimation of luminal solubility of ketoconazole and danazol in 
the pooled sample reflecting HIFmedian (Figure 4). 
For indomethacin, solubility was underestimated in all cases, due to the higher than average pH of the 
pooled samples reflecting HIFmean and HIFmedian; pH has much greater impact on indomethacin solubility 
than the rest of APIs tested in the present study, due to its specific ionization properties (Table 1, Figures 3 
and 4). 
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Figure 3. Mean+SD (n=3) values for solubility of ketoconazole (A), indomethacin (B), and danazol (C) in the pooled HIF 
sample reflecting HIFmean, and in various simulated intestinal fluids (37 
o
C). Please see Table 2 and text for 
composition of simulated intestinal fluids. 
 
 













































































































Figure 4. Mean+SD (n=3) values for solubility of ketoconazole (A), indomethacin (B) and danazol (C) in the pooled HIF 
sample reflecting HIFmedian and in FaSSIFcr-V2Plusmedian. 
Concluding remarks 
Estimation of solubility in median environment of upper small intestine in the fasted state seems 
adequate by data collected in FaSSIF-V2plusmedian. In contrast, if solubility in the mean environment of 
upper small intestine is to be estimated, consideration of additional luminal characteristics is required, e.g. 
buffering species identity [18], non-micellar colloidal lipid structures [19], and lyso-phosphatidylcholine 
content [20]. Perhaps a practical methodology to balance the lack of simulation of certain luminal 
components in FaSSIF-V2 might be the use of FaSSIF-V2 with high phosphatidylcholine concentration, e.g. 
1mM. 
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